Experimental Alzheimer's drug could slow cognitive decline in patients, early results suggest
CNN
Eli Lilly and Company's experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer's disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday.
The study included 257 patients with early symptomatic Alzheimer's disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science officer at the Alzheimer's Association, who was not involved in the study.Senate Democrats have confirmed some of President Joe Biden’s picks for the federal bench this week in the face of President-elect Donald Trump’s calls for a total GOP blockade of judicial nominations – in part because several Republicans involved with the Trump transition process have been missing votes.
Donald Trump is considering a right-wing media personality and people who have served on his US Secret Service detail to run the agency that has been plagued by its failure to preempt two alleged assassination attempts on Trump this summer, sources familiar with the president-elect’s thinking tell CNN.
President-elect Donald Trump’s new Department of Government Efficiency, a nongovernmental entity helmed by billionaire Elon Musk and biotech entrepreneur and former Republican presidential candidate Vivek Ramaswamy, is expected to make a push for an end to remote work across federal agencies as a way to help reduce the federal workforce through attrition.